**PHARMACY TRIAL PROGRAM (PTP)**

**UPDATE –HEALTH**

**AN OVERVIEW OF THE PTP AND CURRENT PROGRESS ON TRIALS**

Mariana Crank

Director, Pharmacy Programs

Natasha Ploenges

Director, Pharmacy Policy and Stakeholder Engagement

Pharmacy Trial Program

* Under the Sixth Community Pharmacy Agreement (6CPA), $50 million has been allocated for a Pharmacy Trial Program (PTP).
* The PTP seeks to improve clinical outcomes for consumers and/or extend the role of pharmacists in the delivery of primary healthcare services.

Listing of PTP Trials

## PTP Tranche 1 trials

* Pharmacy Diabetes Screening Trial (Diabetes Trial)
* Indigenous Medication Review Service Feasibility Study (IMeRSe Feasibility Study Trial)

## PTP Tranche 2 trials

* Getting Asthma Under Control Trial
* Integrating Pharmacists into Aboriginal Community Controlled Health Services (the IPAC Project)
* Reducing Medicine Induced Deterioration and Adverse Reactions Trial (the ReMInDARTrial)
* Early Detection and Management of Cardiovascular Disease Risk Factors and Chronic Disease Markers in Community Pharmacy Trial (CVD Trial)

## PTP Tranche 3 trial

* Chronic Pain MedsCheckTrial.
* Bridging the Gap between Physical and Mental Illness in Community Pharmacy Trial (PharMIbridgeTrial)

Assessment of Trial Proposals and Outcomes

* A Trial Advisory Group (TAG) was established as an independent expert advisory committee to provide advice to the Department on the development and implementation of trials under the PTP.
* To inform TAG’s recommendations, trial protocols were provided to the Protocol Advisory Sub Committee (PASC) of the Medical Services Advisory Committee (MSAC) for comment to ensure that appropriate evidence would be gathered throughout trials to inform independent evaluations of cost-effectiveness on their completion.
* Following completion of each trial, rigorous evaluation by an independent health technology assessment (HTA) body will also be undertaken to determine the effectiveness and cost-effectiveness of the trial intervention.

Pharmacy Trial Program

* The Department acknowledges the engagement of all Trial Sponsors, pharmacists and project teams participating in the trials and their efforts to find strategies to overcome barriers to undertake the trials.
* Common across the trials have been delays encountered in the early development stages.
* Issues that have delayed the implementation of trials under the PTP have included the time required to:
	+ refine trial protocols to meet the requirements of prospective HTA evaluations; and
	+ seek ethics approval from Human Research Ethic Committees.
* For various reasons, many trials have also had to review their original anticipated sample sizes.

Pharmacy Trial Program – Update

This overview provides an update of the following trials:

* Getting Asthma Under Control Trial
* Integrating Pharmacists into Aboriginal Community Controlled Health Services (the IPAC Project)
* Early Detection and Management of Cardiovascular Disease Risk Factors and Chronic Disease Markers in Community Pharmacy Trial (CVD Trial)
* Reducing Medicine Induced Deterioration and Adverse ReactionsTrial (the ReMInDARTrial)

Getting Asthma Under Control Trial

## Background

* Led by the WoolcockInstitute of Medical Research in partnership with the Guild, the Pharmaceutical Society of Australia (PSA) and the National Asthma Council.
* Based in NSW, WA and TAS, the trial aims to assist patients with uncontrolled asthma and help them better manage their medication use and inhaler technique.
* It was originally expected 80 community pharmacies and over 550 patients would be recruited.

Getting Asthma Under Control Trial

## Current Status

* Pharmacist recruitment commenced on 2 Jul 2018 and service delivery commenced in Sep 2018.
* Patient recruitment ceased on 28 Feb 2019.
* A total of 92 pharmacies and 377 patients have been recruited. No patients have been ‘lost’ during follow-up.
* The Final Report is expected to be delivered 30 Jun 2020.

Integrating Pharmacists into Aboriginal Community Controlled Health Services Project (The IPAC Project)

**Background**

* Led by the PSA in partnership with the National Aboriginal Community Controlled Health Organisation (NACCHO) and James Cook University.
* The project aims to have pharmacists provide medication management services to Aboriginal and Torres Strait Islander people and support other health professionals in providing these services.
* The original Trial design estimated a sample size of 7,766 patients, working on 6 interactions per day of pharmacist activity.
* The total estimated sample size of patients however, had to be revised to 1,200.
* It was also originally anticipated that the Trial would involve 22 ACCHS sites and a total of 10 FTE pharmacists across Vic, Qld and the NT.

IPAC PROJECT

## Current Status

As at 30 June 2019:

* 18 ACCHSs are involved in the project, and 22 pharmacists are delivering trial services across 23 sites; and
* Over 1,400 patients have consented to participate in the IPAC Project –this has exceeded the revised projected total number of 1,200 patients.
* Trial sites are now entering the follow-up phase of the intervention where they prioritise repeat encounters with participants.
* The Final Report is expected to be delivered 30 Apr 2020.

Reducing Medicine Induced Deterioration and Adverse Reactions (ReMInDAR) Trial

## Background

* Led by the University of South Australia and delivered in collaboration with Terry White Chemmart, Southern Cross Care and Helping Hand Aged Care.
* Basedin SA and Tas, the trial aims to enable early identification of signs and symptoms of medicine induced deterioration, through pharmacists assessing the patient’s medication regime in Residential Aged Care Facilities (RACFs).
* It was originally anticipated that 500 RACF patients would be recruited.

Reducing Medicine Induced Deterioration and Adverse Reactions (ReMInDAR) Trial

## Current Status

* 39 RACFs have been recruited to participate in the trial.
* The Trial’s patient sample size had to be revised down from 500 to 354 patients from the originally proposed sample size, mostly due to many RACF residents being too frail to participate in the Trial.
* Pharmacist intervention will be completed by end Jun 2020.
* The Final Report is expected to be delivered to the Department in Sep 2020.

Early Detection and Management of Cardiovascular Disease Risk Factors and Chronic Disease Markers in Community Pharmacy (CVD Trial)

## Background

* Led by Black Swan Health, this trial aims to identify patients at risk of cardiovascular disease (CVD) through an integrated health check delivered in community pharmacy to detect risk, diagnose and enable early intervention for cardiovascular disease.
* The community pharmacy will be integrated with general practice and other providers to ensure individuals with elevated risk status are offered appropriate treatment to reduce their overall CVD risk and improve quality of care.
* It was originally anticipated that the trial would take place in a minimum of 10, and up to 20, community pharmacies across metropolitan Perth and up to 3,000 patients would be recruited.
* To account for the delays, a reduced total sample size of around 1,280 -2,200 is likely to be achieved.

CVD Trial

## Current Status

* Trial services have not yet commenced.
* Trial services are expected to start shortly –later this month or next.

**6CPA PHARMACY TRIALS PROGRAMS**

Marsha Gomez

National Manager –Programs

The Pharmacy Guild of Australia

GUILD UPDATE

* Pharmacy Diabetes Screening Trial
* Aboriginal and Torres Strait Islander Medication Review Service (IMeRSe)
* Chronic Pain MedsCheck Trial
* Bridging the Gap between Physical and Mental Illness in Community Pharmacy (PharmMIbridge)

The Pharmacy Trial Programs are funded by the Australian Government Department of Health as part of the Sixth Community Pharmacy Agreement.

Pharmacy Diabetes Screening Trial

## Aim

To test the comparative clinical and cost effectiveness of three models of a pharmacy-based opportunistic risk assessment, screening and referral service for type 2 diabetes in a previously undiagnosed population.

Expert Panel

* Professor Stephen Colagiuri, The Boden Institute at the University of Sydney (Chair)
* Dr Gary Deed, The Royal Australian College of General Practitioners
* Associate Professor Sof Andrikopoulos, Australian Diabetes Society
* Adjunct Professor Greg Johnson, Diabetes Australia
* Nicole Frayne, Australian Diabetes Educators Association
* Amanda Galbraith, Community Pharmacist (Diabetes Educator)
* Teresa Di Franco, Pharmaceutical Society of Australia (Diabetes Educator)
* Emeritus Professor Lloyd Sansom AO, Department of Health
* Natasha Ploenges, Department of Health

Aboriginal and Torres Strait Islander Medication Review Service: A Feasibility Study

## Aim

To promote health and wellbeing by optimising an individual’s medication management through a culturally responsive medication review service delivered by community pharmacists integrated with Aboriginal Health Services as part of holistic care.

Expert Panel

* Associate Professor Ray Lovett, Australian National University (Chair)
* Dr Carmel Nelson, Institute for Urban Aboriginal and Torres Strait Islander Health
* Mr Daniel Williamson, Aboriginal and Torres Strait Islander Health Branch, Queensland Health
* Dr Peter Tenni, University of Tasmania
* A/Professor Lindy Swain, University of Notre Dame
* Hannah Mann, The Pharmacy Guild of Australia
* Kellie Beckenham, Practicing Community Pharmacist
* Dr Christine Connors, Northern Territory Government
* Sue Carson, Pharmaceutical Society of Australia
* Natasha Ploenges, Department of Health
* Emeritus Professor Lloyd Sansom AO, School of Pharmacy and Medical Sciences, University of South Australia

Chronic Pain MedsCheck Trial

## Aim

To assess the effectiveness of a pharmacist-led, patient-centred service to support patients that are taking medication to manage chronic pain and are identified as experiencing self-management or pain medication dependency issues.

Expert Panel

* Nick Logan, Practicing Community Pharmacist (Chair)
* Helen O’Byrne, The Pharmacy Guild of Australia
* Joyce McSwan, Pain expert
* Benjamin Graham, Chronic Pain Australia
* Debbie Rigby, Pharmaceutical Society of Australia
* Royal Australian College of General Practitioners (invited)
* The Faculty of Pain Medicine, Australian and New Zealand College of Anaesthetists (invited)
* Emeritus Professor Lloyd Sansom AO, Department of Health
* Dr Lisa Fodero, HealthConsult
* Dr Hilarie Tardiff, University of Wollongong
* Fiona Hodson, Australian Pain Society

Bridging the Gap between Physical and Mental Illness in Community Pharmacy – PharMIbridge

## Aim

A Randomised Controlled Trial of a community pharmacy support service focussed on medicine adherence strategies and physical health for people living with severe and persistent mental illness.